|Articles|June 25, 2015

Outlook: Market Access in Australia

Despite recent challenges, the Australian market still offers a number of opportunities for pharma manufacturers.

Australia is a country that has challenged pharmaceutical manufacturers in recent years with extensive government reforms in drug pricing, unpredictability around reimbursement and pricing decisions, and other structural changes. Despite these challenges, the Australian market still offers a number of opportunities for manufacturers.

This BioPharmaceutical International article by Michael J. Kuchenreuther and Jill E. Sackman looks at those opportunities.

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!

Outlook: Market Access in Australia

Newsletter

Related Content

How Are Global Regulatory Agencies Adjusting Their Policies for Biosimilars?

When Borders Become Bottlenecks: How Pharma Should Adapt to the New Geopolitical Lens

Korea and Australia's P&MA Shift: From Local Launch Opportunities to Regional Blueprint

AstraZeneca Stock Becomes UK’s Biggest Stock

Basel, Switzerland, Puts Out Call for Pharma Execs

Trending on PharmExec

Lilly’s Orforglipron, Retatrutide Named as Defining GLP-1 Drugs of the Next Decade

Roundup: Pharma’s Funding Surge Ahead of J.P. Morgan 2026

Johnson & Johnson Reaches Agreement with Trump Administration, Continues $55 Billion US-Based Investment Plan

FDA Limits Regulations on Non-Medical Grade Wearable Fitness Devices

How is Re-Vana Using its Sustained-Delivery Hydrogel Technology to Position Itself as a Long-Term Partner at the 2026 J.P. Morgan Healthcare Conference?